WHAT CLINICAL DOSE ACTUALLY MEANS

The Problem the Phrase Is Trying to Solve

When researchers test a compound in animals, they pick a dose based on the animal's metabolism, surface area, and the goal of the experiment. The dose is reported as milligrams per kilogram of body weight (mg/kg). When that finding gets used to inform a human supplement dose, three conversions have to happen: animal to human (which is not 1:1), kg to milligrams (which depends on body weight), and route to bioavailability (which depends on whether the published research used oral, IV, or other delivery, and what fraction of an oral dose reaches circulation in humans).

A "clinical dose" is the dose that, after all those conversions, lands at the level where the published mechanism actually operates in a human body. If the conversion is done sloppily or skipped entirely, the label dose can sit substantially below the functional dose with no warning to the consumer. (this is the part of supplement formulation that took me longest to internalize, because the math is unintuitive and the supplement industry has every incentive to keep it opaque.)

Animal-to-Human Conversion

The standard correction for rat-to-human dose translation is based on body surface area, not body weight, and the typical adjustment factor is roughly 6.2x lower in human dose for a given mg/kg rat dose. For mice, the factor is closer to 12x. So a 10 mg/kg rat dose corresponds to roughly 1.6 mg/kg in a human, which lands at about 110 mg for a 70 kg adult. The same 10 mg/kg dose in mice would correspond to roughly 0.8 mg/kg in a human, which is half that.

The conversion factors are imperfect approximations, in the published animal-to-human extrapolation literature at least. They get you to the right order of magnitude, not to a precise dose, which is part of why supplement formulation involves a margin built into the input dose.

Bioavailability Adjustment

The bioavailability haircut is the second multiplier. For DHM, absolute oral bioavailability is approximately 4 percent in standard formulations ². So if your surface-area-converted target is 110 mg of in-circulation DHM, you need to load roughly 25x that as input dose -- about 2,750 mg -- to deliver the target. With a delivery-format improvement (like fulvic acid chelation or lipid nanocarriers), the haircut shrinks and the input dose can come down ³.

The Shen 2012 rat dosing of 1-10 mg/kg ¹, the surface-area conversion to roughly 1.6 mg/kg in humans, and the 4 percent bioavailability haircut are the three numbers that combine to produce the 1,000-1,500 mg DHM dose target in a real-world supplement format. None of those numbers are mysterious. They are just rarely shown together.

Why Higher Animal Doses Get Used in Newer Studies

A 2023 study examining DHM and ethanol-induced lipid accumulation used DHM at the equivalent of hundreds of milligrams per kilogram in mice to get a clean signal on hepatic outcomes ⁴. After mouse-to-human conversion, that lands at human-equivalent doses well above what any retail product currently delivers. This is the trend in the more recent DHM literature -- as researchers map dose-response more carefully, the doses needed for measurable downstream effects keep going up.

What This Page Is Not Claiming

The clinical-dose math is not exact. There is real biological variability between individuals, between species, and between formulation routes. The math gets you to the right order of magnitude with appropriate margin, not to a precise per-individual dose. The difference between a label dose and a functional dose si almost entirely about whether anyone did the conversion math.

For the DHM-specific dose math worked through end-to-end, see DHM Dose-Response. For the bioavailability problem that drives most of the haircut, see DHM Bioavailability.